The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just Added
£ 10k
2736 @ 364.93
Good luck what ever your call
Well I'm still adding
They have significant cash at bank and delivered £ 76m in Q1
If this is all the business is worth then there is no hope for anything on AIM frankly
Good Luck what ever your call
Pork's
Fair play HarChris. If i had the capital to average down i would! Good luck man!
It has, plain and simple. Profit warnings invariably cause sell offs. Investors will not hold shares in the company during periods of such uncertainty. There will be many on the sidelines waiting for more clarity before making their next move.
As the share price falls I am choosing to take the risk and buy more as I think barring some extreme escalation/development I will make considerable returns on any investment I make at £3.65 a share.
Yup, and the £36m per Qtr averages to £400,000 per day, probably more now.
No debts with a growing Product range.
Loads of companies would like that!!!
HarChris struggle to believe a dispute have wiped over 50% of value off if DHSC was already priced in. Given that 50% of sales were elsewhere in Q1.
1,butcher i am reminded of a previous discussion where people were trying to tell me that opinion and fact were the same thing!!!!!
50% of the first quarters revenue was private and worldwide sells. 36 million pounds. And probably growing. The house broker s.p .angel was very surprised at how strong they were.
Nova Sight, personally I think the lack of contract extension was more or less priced in. What wasn't was the dispute and the possible material impact on the full year results...
Yeah bad value
To allot of posters who give their opinions stated as fact.. please post some fact. It would be appreciated.
'22billion allocated not spent and you have to be chosen to get any share of that. Are Novacyt? Would suggest this is looking more and more unlikely.'
Yes, they are an approved supplier on the 3bn tender with an newly established sales network in place to capitalise. Disputes happen on contracts, that's why the process is written into them. It would be folly for the government to put overall testing capacity at risk by blacklisting a company who has provided so much to that. Additionally, they have private sector customers who have been approved as suppliers on the 15bn framework so even if the gov don't award NCYT any direct work they'll still supply into the tender indirectly.
Whatever the reason and justification, one things for sure its spectacular value
HArChris, true in most cases. Unfortunately the same was said at 800p that the DHSC not being extended was priced in. Evidently not hence the further drop to where we are now.
Companies valued at £250m are very rarely profit making and when they are that profit is usually about £10m. You don't have to be selective to see this is true. This valuation is 'assuming' there is serious further damaging news to come, it is pricing it in already.
22billion allocated not spent and you have to be chosen to get any share of that. Are Novacyt? Would suggest this is looking more and more unlikely.
Chris, it's mad isn't it?! In a month's time the issue with DHSC could be resolved, new tenders revealed and the strategic long term plan laid out. Sure there's some risk still evidently but I'm adding one last time at 366...
£22Bn (and counting) of allocated government funds to testing over the next 4 years would suggest its only getting started. The private sector will likely pick up a bigger tab!
Is it madness or is it just because the upside is disappearing. It does not seem that Novacyt have managed to take full advantage of the opportunity of a lifetime.
On 17th Sep 2020 the company announced that it generated 72m euro in revenue and the SP was 375-385p.
They generated more in the first Quarter of 2021 an the SP is currently lower. Madness.